LOX and nonpapillary renal cell carcinoma: As shown in Fig. 4, ccRCC patients with high expression of C3 (HR1.51, 95% CI: 1.12–2.03, P = 0.0067), LOX (HR1.61, 95% CI: 1.18–2.19, P = 0.0022), CXCR4 (HR1.67, 95% CI: 1.24–2.26, P = 0.00068), and CP (HR1.54, 95% CI: 1.13–2.1, P = 0.0064) usually have a lower overall survival rate.